Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease
Elizabeth Stenger, Cynthia R Giver, Amelia Langston, Daniel Kota, Pankoj Kumar Das, Raghavan Chinnadurai, Jacques Galipeau, Edmund K Waller, Muna Qayed, Elizabeth Stenger, Cynthia R Giver, Amelia Langston, Daniel Kota, Pankoj Kumar Das, Raghavan Chinnadurai, Jacques Galipeau, Edmund K Waller, Muna Qayed
Abstract
Despite the curative potential of hematopoietic cell transplantation (HCT) for hematologic malignancies, graft-versus-host disease (GVHD) remains a substantial cause of morbidity and mortality, particularly if treatment is refractory. Treatment with additional immunosuppression including steroids often leads to opportunistic infections and organ dysfunction. Novel therapies are greatly needed, specifically ones that lead to responses in treatment-refractory patients and are better tolerated. Mesenchymal stromal cells (MSCs) are non-hematopoietic tolerogenic cells present in normal bone marrow (BM), which can be expanded ex vivo to therapeutic doses. Their safety and efficacy have been assessed in inflammatory disorders including GVHD, but heterogeneity in clinical responses has led some to examine MSC manufacturing and administration procedures, which may impact in vivo efficacy. We hypothesized that autologous, early-passage, and culture-recovered (after freeze and thaw) MSCs would be safe and may have superior efficacy. In this phase I single-center trial, we assessed MSC safety and early efficacy of an escalating number of doses (2 × 106/kg doses; dose level 1, single dose; dose level 2, two weekly doses; dose level 3, four weekly doses) in patients aged ≥12 years with treatment-refractory acute or chronic GVHD. Eleven enrolled patients received some or all planned MSC infusions, with a median age at enrollment of 37 years. The most common primary HCT indication was leukemia, and the median time from HCT to first MSC infusion was 2.6 years. MSC infusion was well tolerated, with all severe adverse events expected and determined to be unlikely or definitely not related to the study. Thus, no dose-limiting toxicities occurred in the three dose levels. Three of four patients with acute GVHD (or overlap with acute features) had responses seen at any timepoint, ranging from partial to complete. In those with a chronic GVHD indication (n = 7), an overall response at 3 months was partial in five, stable in one, and progressive in one. No appreciable differences were seen between dose levels in peripheral blood lymphocyte subsets. In conclusion, autologous and culture-recovered MSCs were safe in the setting of refractory GVHD following HCT for hematologic malignancy, and clinical responses were most notable in patients with acute GVHD.
Keywords: Hematologic malignancy; Mesechymal stromal cell; acute graft versus host disease (aGVHD); allogeneic transplant of haematopoietic stem cells; chronic graft versus host disease (GVHD).
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2022 Stenger, Giver, Langston, Kota, Das, Chinnadurai, Galipeau, Waller and Qayed.
Figures
References
- D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. . Current use of and trends in hematopoietic cell transplantation in the united states. Biol Blood Marrow Transplant (2020) 26(8):e177–82. doi: 10.1016/j.bbmt.2020.04.013
- El Jurdi N, Rayes A, MacMillan ML, Holtan SG, DeFor TE, Witte J, et al. . Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. Blood Adv (2021) 5(5):1352–9. doi: 10.1182/bloodadvances.2020003937
- Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 12(5):383–96. doi: 10.1038/nri3209
- Kelly K, Rasko JEJ. Mesenchymal stromal cells for the treatment of graft versus host disease. Front Immunol (2021) 12:761616. doi: 10.3389/fimmu.2021.761616
- Murata M, Terakura S, Wake A, Miyao K, Ikegame K, Uchida N, et al. . Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone marrow Transplant (2021) 56(10):2355–66. doi: 10.1038/s41409-021-01304-y
- Kurtzberg J, Prockop S, Chaudhury S, Horn B, Nemecek E, Prasad V, et al. . Study 275: Updated expanded access program for remestemcel-l in steroid-refractory acute graft-versus-Host disease in children. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant (2020) 26(5):855–64. doi: 10.1016/j.bbmt.2020.01.026
- Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. . A phase 3 randomized study of remestemcel-l versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-Host disease. Biol Blood marrow Transplant (2020) 26(5):835–44. doi: 10.1016/j.bbmt.2019.08.029
- Galipeau J. Mesenchymal stromal cells for graft-versus-Host disease: A trilogy. Biol Blood Marrow Transplant (2020) 26(5):e89–91. doi: 10.1016/j.bbmt.2020.02.023
- Francois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy (2012) 14(2):147–52. doi: 10.3109/14653249.2011.623691
- Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, et al. . Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells (2016) 34(9):2429–42. doi: 10.1002/stem.2415
- Cottle C, Porter AP, Lipat A, Turner-Lyles C, Nguyen J, Moll G, et al. . Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal Stromal/Stem cells and other common cellular therapeutics. Curr Stem Cell Rep (2022) 8(2):72–92. doi: 10.1007/s40778-022-00212-1
- von Bahr L, Sundberg B, Lonnies L, Sander B, Karbach H, Hagglund H, et al. . Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant (2012) 18(4):557–64. doi: 10.1016/j.bbmt.2011.07.023
- Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood (2005) 106(13):4057–65. doi: 10.1182/blood-2005-03-1004
- Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. . Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood (2003) 101(9):3722–9. doi: 10.1182/blood-2002-07-2104
- Copland IB, Qayed M, Garcia MA, Galipeau J, Waller EK. Bone marrow mesenchymal stromal cells from patients with acute and chronic graft-versus-Host disease deploy normal phenotype, differentiation plasticity, and immune-suppressive activity. Biol Blood Marrow Transplant (2015) 21(5):934–40. doi: 10.1016/j.bbmt.2015.01.014
- Dhere T, Copland I, Garcia M, Chiang KY, Chinnadurai R, Prasad M, et al. . The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory crohn's disease - a phase 1 trial with three doses. Alimentary Pharmacol Ther (2016) 44(5):471–81. doi: 10.1111/apt.13717
- Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. . National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant (2015) 21(3):389–401.e1. doi: 10.1016/j.bbmt.2014.12.001
- Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. . Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PloS One (2012) 7(10):e47559. doi: 10.1371/journal.pone.0047559
- Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y, et al. . Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep (2018) 22(9):2504–17. doi: 10.1016/j.celrep.2018.02.013
- Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. . Ruxolitinib for glucocorticoid-refractory acute graft-versus-Host disease. New Engl J Med (2020) 382(19):1800–10. doi: 10.1056/NEJMoa1917635
- Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. . Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood (2020) 135(20):1739–49. doi: 10.1182/blood.2020004823
- Martini DJ, Chen YB, DeFilipp Z. Recent FDA approvals in the treatment of graft-Versus-Host disease. Oncologist (2022) 27(8):685–93. doi: 10.1093/oncolo/oyac076
- Huang EY, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, et al. . Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflammatory Bowel Dis (2015) 21(5):963–72. doi: 10.1097/mib.0000000000000332
- Holtan SG, Hoeschen AL, Cao Q, Arora M, Bachanova V, Brunstein CG, et al. . Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Adv (2020) 4(7):1284–95. doi: 10.1182/bloodadvances.2019001259
- Holtan SG, Ustun C, Hoeschen AL, Feola J, Cao Q, Gandhi P, et al. . Phase 2 results of urinary-derived human chorionic Gonadotropin/Epidermal growth factor as treatment for life-threatening acute GVHD. Blood (2021) 138(1):261. doi: 10.1182/blood-2021-145008
- Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol (Baltimore Md 1950) (2014) 192(4):1491–501. doi: 10.4049/jimmunol.1301828
- Guess AJ, Daneault B, Wang R, Bradbury H, La Perle KM, Fitch J, et al. . Safety profile of good manufacturing practice manufactured interferon γ-primed mesenchymal Stem/Stromal cells for clinical trials. Stem Cells Trans Med (2017) 6(10):1868–79. doi: 10.1002/sctm.16-0485
Source: PubMed